Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926004 | 0.86 | MC4R (0.52) | MC4RKMT2AMEN1LMNAKDM4E | |
| SCHEMBL9926006 | 0.85 | KMT2A (0.58) | MC4RKMT2AMEN1LMNAKDM4E | |
| SCHEMBL13987582 | 0.83 | KMT2A (0.50) | MC4RKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL9926057 | 0.81 | SMN1; SMN2 (0.52) | MC4RKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL9926010 | 0.81 | KMT2A (0.48) | MC4RKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL9926129 | 0.81 | MEN1 (0.47) | MC4RKMT2AMEN1LMNAKDM4E | |
| SCHEMBL9926007 | 0.79 | POLB (0.52) | MC4RKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL13987584 | 0.77 | THRB (0.56) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL9926042 | 0.77 | POLB (0.56) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL5266456 | 0.73 | MEN1 (0.45) | MC4RKMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836180-B1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2012-06-13 | — | — | EP | disclosed |
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SLC5A1, SLC5A2, KCNJ1 | MC4R 1509/4885KMT2A 4211/4885MEN1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.